Terms: = Colorectal cancer AND RET, RET51, 5979, P07949, ENSG00000165731, MTC1, MEN2A, RET-ELE1, HSCR1, MEN2B, CDHF12 AND Treatment
48 results:
1. Cribriform morular thyroid carcinoma: Clinicopathological and molecular basis for both a preventive and therapeutic approach for a rare tumor (Review).
Cameselle-García S; Abdulkader-Nallib I; Sánchez-Ares M; Cameselle-Teijeiro JM
Oncol Rep; 2024 Sep; 52(3):. PubMed ID: 39027989
[TBL] [Abstract] [Full Text] [Related]
2. Progress in clinical diagnosis and treatment of colorectal cancer with rare genetic variants.
Chen S; Gu J; Wu K; Zhao X; Lu Y
Cancer Biol Med; 2024 Jun; 21(6):473-83. PubMed ID: 38940668
[TBL] [Abstract] [Full Text] [Related]
3. Fruquintinib as new treatment option in metastatic colorectal cancer patients: is there an optimal sequence?
Stucchi E; Bartolini M; Airoldi M; Fazio R; Daprà V; Mondello G; Prete MG; Puccini A; Santoro A
Expert Opin Pharmacother; 2024 Mar; 25(4):371-382. PubMed ID: 38568032
[TBL] [Abstract] [Full Text] [Related]
4. Regorafenib and glioblastoma: a literature review of preclinical studies, molecular mechanisms and clinical effectiveness.
Mongiardi MP; Pallini R; D'Alessandris QG; Levi A; Falchetti ML
Expert Rev Mol Med; 2024 Apr; 26():e5. PubMed ID: 38563164
[TBL] [Abstract] [Full Text] [Related]
5. Concurrent KRAS p.G12C mutation and ANK3::ret fusion in a patient with metastatic colorectal cancer: a case report.
Bedau T; Heydt C; Siebolts U; Zander T; Kraemer M; Loeser H; Buettner R; Quaas A
Diagn Pathol; 2024 Mar; 19(1):55. PubMed ID: 38539256
[TBL] [Abstract] [Full Text] [Related]
6. Baseline ctDNA gene alterations as a biomarker of survival after panitumumab and chemotherapy in metastatic colorectal cancer.
Shitara K; Muro K; Watanabe J; Yamazaki K; Ohori H; Shiozawa M; Takashima A; Yokota M; Makiyama A; Akazawa N; Ojima H; Yuasa Y; Miwa K; Yasui H; Oki E; Sato T; Naitoh T; Komatsu Y; Kato T; Mori I; Yamanaka K; Hihara M; Soeda J; Misumi T; Yamamoto K; Yamashita R; Akagi K; Ochiai A; Uetake H; Tsuchihara K; Yoshino T
Nat Med; 2024 Mar; 30(3):730-739. PubMed ID: 38347302
[TBL] [Abstract] [Full Text] [Related]
7. Impact of tissue-agnostic approvals on management of primary brain tumors.
Ahluwalia MS; Khosla AA; Ozair A; Gouda MA; Subbiah V
Trends Cancer; 2024 Mar; 10(3):256-274. PubMed ID: 38245379
[TBL] [Abstract] [Full Text] [Related]
8. Negative hyperselection of elderly patients with RAS and BRAF wild-type metastatic colorectal cancer receiving initial panitumumab plus FOLFOX or 5-FU/LV.
Pietrantonio F; Bergamo F; Rossini D; Ghelardi F; De Grandis MC; Germani MM; Barsotti G; Formica V; Frassineti GL; Boscolo G; Cinieri S; Di Donato S; Antonuzzo L; Antoniotti C; Ambrosini M; Piva VM; Nichetti F; Fassan M; Cremolini C; Lonardi S
Eur J Cancer; 2023 Dec; 195():113396. PubMed ID: 37924647
[TBL] [Abstract] [Full Text] [Related]
9. Clinical Characteristics and Responses to Immune Checkpoint Inhibitors in ret-Aberrant Digestive Tract Tumours.
Yen CC; Yeh YM; Huang HY; Ting YL; Fu PA; Lin TC; Liu IT; Yen CJ
Target Oncol; 2023 Jul; 18(4):611-623. PubMed ID: 37347391
[TBL] [Abstract] [Full Text] [Related]
10. FDA Approval Summary: Selpercatinib for the treatment of Advanced ret Fusion-Positive Solid Tumors.
Duke ES; Bradford D; Marcovitz M; Amatya AK; Mishra-Kalyani PS; Nguyen E; Price LSL; Fourie Zirkelbach J; Li Y; Bi Y; Kraft J; Dorff SE; Scepura B; Stephenson M; Ojofeitimi I; Nair A; Han Y; Tezak Z; Lemery SJ; Pazdur R; Larkins E; Singh H
Clin Cancer Res; 2023 Sep; 29(18):3573-3578. PubMed ID: 37265412
[TBL] [Abstract] [Full Text] [Related]
11. Personalized Systemic Therapies in Hereditary cancer Syndromes.
Mastrodomenico L; Piombino C; Riccò B; Barbieri E; Venturelli M; Piacentini F; Dominici M; Cortesi L; Toss A
Genes (Basel); 2023 Mar; 14(3):. PubMed ID: 36980956
[TBL] [Abstract] [Full Text] [Related]
12. Application of histology-agnostic treatments in metastatic colorectal cancer.
Sartore-Bianchi A; Agostara AG; Patelli G; Mauri G; Pizzutilo EG; Siena S
Dig Liver Dis; 2022 Oct; 54(10):1291-1303. PubMed ID: 35701319
[TBL] [Abstract] [Full Text] [Related]
13. Comprehensive genomic profiling in advanced/metastatic colorectal cancer: number needed to test and budget impact of expanded first line use.
Proudman D; DeVito NC; Belinson S; Allo MA; Morris ED; Signorovitch J; Patel AK
J Med Econ; 2022; 25(1):817-825. PubMed ID: 35593483
[TBL] [Abstract] [Full Text] [Related]
14. The Genomics of colorectal cancer in Populations with African and European Ancestry.
Myer PA; Lee JK; Madison RW; Pradhan K; Newberg JY; Isasi CR; Klempner SJ; Frampton GM; Ross JS; Venstrom JM; Schrock AB; Das S; Augenlicht L; Verma A; Greally JM; Raj SM; Goel S; Ali SM
Cancer Discov; 2022 May; 12(5):1282-1293. PubMed ID: 35176763
[TBL] [Abstract] [Full Text] [Related]
15. Anticancer drug resistance: An update and perspective.
Nussinov R; Tsai CJ; Jang H
Drug Resist Updat; 2021 Dec; 59():100796. PubMed ID: 34953682
[TBL] [Abstract] [Full Text] [Related]
16. How does nintedanib overcome cancer drug-resistant mutation of ret protein-tyrosine kinase: insights from molecular dynamics simulations.
Cao S; Jiang X; Tan C; Fu M; Xiong W; Ji D; Lv J
J Mol Model; 2021 Nov; 27(11):337. PubMed ID: 34725737
[TBL] [Abstract] [Full Text] [Related]
17. Identification of ret fusions in a Chinese multicancer retrospective analysis by next-generation sequencing.
Shi M; Wang W; Zhang J; Li B; Lv D; Wang D; Wang S; Cheng D; Ma T
Cancer Sci; 2022 Jan; 113(1):308-318. PubMed ID: 34710947
[TBL] [Abstract] [Full Text] [Related]
18. cancer Therapy Guided by Mutation Tests: Current Status and Perspectives.
Aleksakhina SN; Imyanitov EN
Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681592
[TBL] [Abstract] [Full Text] [Related]
19. Genomic characterization of hepatoid tumors: context matters.
Lawlor RT; Mafficini A; Sciammarella C; Cantù C; Rusev BC; Piredda ML; Antonello D; Grimaldi S; Bonizzato G; Sperandio N; Marchegiani G; Malleo G; Pea A; Salvia R; Mombello A; Mazzoleni G; Nottegar A; Hanspeter E; Riva G; Tomezzoli A; Bencivenga M; de Manzoni G; Pedron S; Paolino G; Mattiolo P; Brosens LA; Silvestris N; Fassan M; Cooke SL; Beer PA; Milella M; Adsay VN; Cheng L; Scarpa A; Luchini C
Hum Pathol; 2021 Dec; 118():30-41. PubMed ID: 34562502
[TBL] [Abstract] [Full Text] [Related]
20. Radiotherapy and immunotherapy converge on elimination of tumor-promoting erythroid progenitor cells through adaptive immunity.
Hou Y; Liang HL; Yu X; Liu Z; Cao X; Rao E; Huang X; Wang L; Li L; Bugno J; Fu Y; Chmura SJ; Wu W; Luo SZ; Zheng W; Arina A; Jutzy J; McCall AR; Vokes EE; Pitroda SP; Fu YX; Weichselbaum RR
Sci Transl Med; 2021 Feb; 13(582):. PubMed ID: 33627484
[TBL] [Abstract] [Full Text] [Related]
[Next]
